Literature DB >> 27025356

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.

Ingrid A Beck1, Rachel Payant1, Nicole Ngo-Giang-Huong2, Woottichai Khamduang3, Laddawan Laomanit4, Gonzague Jourdain2, Lisa M Frenkel5.   

Abstract

Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  HBV drug resistance; HBV treatment; Lamivudine resistance; Oligonucleotide ligation assay

Mesh：

Substances：

Year:  2016        PMID： 27025356      PMCID： PMC5074383          DOI： 10.1016/j.jviromet.2016.03.014

Source DB:  PubMed          Journal:  J Virol Methods        ISSN： 0166-0934            Impact factor:   2.014


  27 in total

Review 1.  Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.

Authors:  Chau-Ting Yeh
Journal:  Antivir Ther       Date:  2010

Review 2.  Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Authors:  Anna S Lok; Fabien Zoulim; Stephen Locarnini; Angeline Bartholomeusz; Marc G Ghany; Jean-Michel Pawlotsky; Yun-Fan Liaw; Masashi Mizokami; Carla Kuiken
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

3.  Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing.

Authors:  Ingrid A Beck; Wenjie Deng; Rachel Payant; Robert Hall; Roger E Bumgarner; James I Mullins; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

4.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.

Authors:  Joseph Torresi; Linda Earnest-Silveira; Georgia Deliyannis; Kristy Edgtton; Hui Zhuang; Stephen A Locarnini; Janet Fyfe; Tina Sozzi; David C Jackson
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

5.  Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.

Authors:  V Thibault; Y Benhamou; C Seguret; M Bochet; C Katlama; F Bricaire; P Opolon; T Poynard; H Agut
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.

Authors:  Gonzague Jourdain; Thor Andrew Wagner; Nicole Ngo-Giang-Huong; Wasna Sirirungsi; Virat Klinbuayaem; Federica Fregonese; Issaren Nantasen; Malee Techapornroong; Guttiga Halue; Ampaipith Nilmanat; Pakorn Wittayapraparat; Veeradet Chalermpolprapa; Panita Pathipvanich; Prapap Yuthavisuthi; Lisa M Frenkel; Marc Lallemant
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

7.  Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Authors:  Evelien Libbrecht; Joke Doutreloigne; Hilde Van De Velde; Man-Fung Yuen; Ching-Lung Lai; Fred Shapiro; Erwin Sablon
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

8.  Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring.

Authors:  Woottichai Khamduang; Catherine Gaudy-Graffin; Nicole Ngo-Giang-Huong; Gonzague Jourdain; Alain Moreau; Thitiporn Borkird; Prapaisri Layangool; Nareerat Kamonpakorn; Weerachai Jitphiankha; Ratchanee Kwanchaipanich; Sathit Potchalongsin; Marc Lallemant; Wasna Sirirungsi; Alain Goudeau
Journal:  J Clin Virol       Date:  2013-08-02       Impact factor: 3.168

9.  Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Authors:  Giovanina M Ellis; Madhumita Mahalanabis; Ingrid A Beck; Gregory Pepper; Amy Wright; Shannon Hamilton; Sarah Holte; Willscott E Naugler; Diane M Pawluk; Chung-Chen Li; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.

Authors:  Woottichai Khamduang; Catherine Gaudy-Graffin; Nicole Ngo-Giang-Huong; Gonzague Jourdain; Alain Moreau; Nuananong Luekamlung; Guttiga Halue; Yuwadee Buranawanitchakorn; Sura Kunkongkapan; Sudanee Buranabanjasatean; Marc Lallemant; Wasna Sirirungsi; Alain Goudeau
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.